Given this, we propose that the increased risk of type 2 diabetes post-COVID-19 is partly related to inflammation-induced upregulation of the glucose transporter SGLT1 in the gut, which could contribute to postprandial hyperglycaemic spikes, insulin resistance and eventually development of type 2 diabetes. The gene discussed is INS; the disease is COVID-19.